Miguel Ruão

Miguel Ruão

Auto-generated profile, based on publicly available information

Miguel Ruão

Department of Ophthalmology of Centro Hospitalar entre Douro e Vouga, Santa Maria da Feira, Portugal

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
MRMiguel Ruão
Miguel Ruão
MAMaría Andreu-Fenoll
María Andreu-Fenoll
Rosa Dolz-Marco PhDRosa Dolz-Marco PhD
Rosa Dolz-Marco PhD
RGRoberto Gallego-Pinazo
Roberto Gallego-Pinazo
Purpose: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases. Methods: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated. Results: A total of 1 (0.012%) culture-proven endophthalmitis and 19 (0.233%) acute intraocular inflammations were registered. In the unilateral injections group, there were 18 (0.274%) acute intraocular inflammations and 1 (0.015%) culture-proven endophthalmitis. One (0.062%) of the 1,612 bilateral same-day injections had a unilateral acute intraocular inflammation, and there were no culture-proven endophthalmitis in this group. Conclusion: Bilateral same-day injections are more convenient for patients and their caregivers than the unilateral injections administered on different days. In our study, the prevalence of culture-proven endophthalmitis and acute intraocular inflammation was lower in the bilateral injections than in the unilateral group. These data support the idea that bilateral same-day injections are a safe and valid treatment to use in our clinical practice.

1 October 2016 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
MRMiguel Ruão
Miguel Ruão
IAInês Almeida
Inês Almeida
RLRaquel Leitão
Raquel Leitão
MAManuela Amorim
Manuela Amorim
MMMadalena Monteiro
Madalena Monteiro
JCJoão Chibante-Pedro
João Chibante-Pedro

28 November 2023 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
CTCarla Teixeira
Carla Teixeira
BPBernardete Pessoa
Bernardete Pessoa
MRMiguel Ruão
Miguel Ruão
JSJoão Paulo Castro Sousa
João Paulo Castro Sousa
SPSusana Penas
Susana Penas
AMAngelina Meireles
Angelina Meireles
Purpose: Persistent diabetic macular edema (DME) remains a problem in clinical practice, with many patients having a suboptimal response to the standard of care (SOC). Evidence supports the long-term efficacy of intravitreal fluocinolone acetonide (FAc) implant (ILUVIEN®) in patients that have responded sub-optimally, although there is still scarce data from real-world Portuguese practices. We aimed to monitor the current SOC in selected Portuguese practices prior to FAc implantation and then assess the long-term effectiveness and safety of the FAc implant. Settings: The study included patient data from five Portuguese public hospitals. Design: This was a non-interventional, multicenter audit of data collected from Retina.pt registry from patients with persistent or recurrent DME despite treatment. Methods: Outcome measures included changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP). Results were compared at regular times over 36 months. Results: This study included 222 eyes from 152 patients. A significant decrease in BCVA (P < 0.001) and a significant increase in CMT (P = 0.013) were observed prior to FAc. A significant increase in BCVA was registered at 6 months after FAc implant administration (P < 0.001), which was maintained during follow-up. No relevant changes in IOP were observed. Treatment burden was reduced as a result of treatment with FAc (P < 0.001 for anti-VEGF, corticosteroids, or both treatments) in the full population. Conclusions: In Portuguese practice, data showed that pre-FAc implantation, some patients did not respond to SOC treatment and/or they were undertreated. Following FAc implant administration, there were rapid, sustained, long-term visual and anatomical improvements, and a marked reduction in treatment burden.

12 June 2025 in International Ophthalmology
Verified
Journal Article
Open access
PDF file
CACatarina Pestana Aguiar
Catarina Pestana Aguiar
JAJoão Alves Ambrósio
João Alves Ambrósio
VMVítor Miranda
Vítor Miranda
MRMiguel Ruão
Miguel Ruão
LDLilianne Duarte
Lilianne Duarte
Purpose This study aims to investigate whether there is a correlation between intraocular pressure (IOP) elevation after intravitreal triamcinolone acetonide (TA) testing and IOP response following fluocinolone acetonide (FAc) implant injection in the treatment of diabetic macular edema. Methods This study employed a real-world observational cohort retrospective design, enrolling patients who had received at least one intravitreal TA injection prior to a FAc implant injection between December 2018 and July 2022. Demographic data, medical and ophthalmic history were collected at baseline. Mean IOP was assessed before and after both treatments and steroid-response was defined as an IOP greater than 21 mmHg. Statistical analysis was performed to determine correlated IOP changes. Results A total of 28 eyes were included in the study. Six eyes exhibited a steroid response following the initial TA injection, and none of these eyes demonstrated a steroid response following the FAc implant. The FAc implant resulted in steroid response in six additional eyes. The analysis revealed no statistically significant correlation between the occurrence of a steroid response following a TA injection and the subsequent mean IOP progression following an FAc implant injection at any time point. No correlation was observed between the variation in IOP following the two treatments. Conclusion It is crucial to evaluate the necessity of a prior short-acting steroid challenge, which carries the risk of multiple disease relapses, given the potential for a prolonged and stable steroid to provide superior control. The predictive value of the test with TA was not evident in our sample, suggesting some usefulness in delaying treatment with the FAc implant.

14 November 2025 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
JAJoão Alves Ambrósio
João Alves Ambrósio
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
MGMariana Garcia
Mariana Garcia
JCJoão Chibante-Pedro
João Chibante-Pedro
MRMiguel Ruão
Miguel Ruão
Introduction Diabetic macular edema (DME) imposes a substantial clinical and psychosocial burden on patients and caregivers due to frequent visits and intravitreal treatments. The fluocinolone acetonide intravitreal implant (Iluvien®) offers sustained drug delivery for up to 3 years. We assessed its real-world impact on vision, macular anatomy, intraocular pressure (IOP), quality of life (QoL), and treatment burden, including caregiver impact. Methods Prospective, real-world observational study of 41 patients with previously treated DME. Assessments occurred at baseline and at 6, 12, 18, 24, and 30 months. Outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), IOP, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite scores. Burden metrics included clinic visits per year and caregiver accompaniment/absenteeism. Results At baseline, mean BCVA was 0.42 ± 0.30 logMAR, CMT 415.8 ± 106.5 µm, IOP 16.6 ± 4.1 mmHg, and NEI VFQ-25 67.6 ± 16.4; 46.3% of patients required caregiver accompaniment, and 61% reported pre-injection anxiety (median duration 2 days). At last follow-up, mean BCVA improved to 0.29 ± 0.26 logMAR (≈+6–7 ETDRS letters; p < 0.001), CMT decreased to 368.1 ± 79.6 µm (p = 0.002), and IOP remained stable at 16.7 ± 4.1 mmHg. The NEI VFQ-25 increased to 77.0 ± 18.0, with a significant main effect of time (repeated-measures analysis of variance (ANOVA), p = 0.001; partial η2 = 0.675); improvements were evident by 6 months and sustained through 30 months (all comparisons p < 0.05). Clinic visits declined from 5.8 ± 1.6 to 3.7 ± 1.5 per year (p < 0.001). Conclusions In a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.

26 January 2017 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Open access
MRMiguel Ruão
Miguel Ruão
MAMaría Andreu-Fenoll
María Andreu-Fenoll
RDRosa Dolz-Marco
Rosa Dolz-Marco
RGRoberto Gallego-Pinazo
Roberto Gallego-Pinazo
To evaluate the prevalence of different optical coherence tomography (OCT) findings in European patients with high myopia. Cross-sectional study conducted in the Macula Unit of the University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 134 myopic eyes of 69 patients (16 males and 53 females) were included. All patients underwent a spectral domain OCT examination at least once. The presence of tractional and atrophic myopic maculopathy and choroidal neovascularization (CNV) was evaluated through OCT scans. The prevalence of tractional myopic maculopathy was found in 53.7% of the eyes. Within this group, 9.7% had foveal retinoschisis, 23.9% extrafoveal retinoschisis, 31.3% internal limiting membrane rigidity, 24.6% epiretinal membrane, and none had vitreomacular traction. The most prevalent OCT finding was chorioretinal atrophy, present in 79.1% of the eyes. Choroidal neovascularization was present in 61.9% of the eyes. There was a trend toward higher prevalence of CNV in eyes with patchy atrophy with foveal involvement compared to those without foveal involvement (81.8% vs 65.5%; P = .103). The prevalence of CNV was quite high, especially in patients with patchy atrophy with foveal involvement.